---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Dosage"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Dosage. Topics: EMERGE regimens: 300 mg every 2 weeks or every 4 weeks, MaGic regimens: weight-based loading dose then 300 mg or 600 mg every 2 weeks, MaGic open-label extension dose, and Highest loading dose used in phase 2. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/dosage"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### EMERGE regimens: 300 mg every 2 weeks or every 4 weeks

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Experimental: Claseprubart Q2W IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).”
> “Experimental: Claseprubart Every 4 weeks (Q4W) IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart or Placebo Q2W starting at Week 1 (Day 8), with doses alternating between claseprubart and placebo.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.2.10.1-2"></a>

### MaGic regimens: weight-based loading dose then 300 mg or 600 mg every 2 weeks

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg or 600mg S.C. Q2W starting Day 7”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

> “15 mg/kg for 300mg arm and 20 mg/kg for 600mg arm.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

> “Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-2.1.2.10.1-3"></a>

### MaGic open-label extension dose

> “All patients entering the OLE received claseprubart 600mg Q2W for varying periods of time before the OLE dose was unified to 300mg Q2W following RCT analysis.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-2.1.2.10.1-4"></a>

### Highest loading dose used in phase 2

> “Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
